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Abstract: A series of (28) 1-alkyl-3-methacryloyl (acryloyl)-benzimidazolone (thione) 
deriv-atives were synthesized. The structures of the new derivatives were confirmed by  
1H-NMR, 
13C-NMR and ESI-MS spectral analysis. The antibacterial activities of these 
compounds against several strains of bacteria, such as Bacillus cereus, Bacillus subtilis, 
Escherichia coli, Staphylococcus aureus and Pseudomonas aeruginosa, were evaluated by 
methods of paper disc-diffusion and broth mciro-dilution. Methacryloyl derivatives 
displayed higher antibacterial activities against tested bacterial strains than those of 
acryloyl derivatives in in vitro tests. A structure-activity relationship (SAR) study revealed 
that the presences of the methacryloyl moieties is essential to the antibacterial activities of 
the compounds.  
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1. Introduction 
With the widespread use of antibiotics, the emergence of resistant bacteria has become a great threat 
to public health [1]. Although there are many approaches to limit the spread of resistant bacteria, the 
development of new antibiotics is undoubtedly a fundamental solution [2]. It is regretful that the number 
of newly approved antibiotics continues to decline, and the majority of compounds under different 
stages are improved variants of marketed antibiotics [3]. Finding good initial lead compounds and 
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progressing compounds into the clinic has proven difficult owing to bottlenecks in the discovery 
pipeline [4]. Benzimidazolone derivatives have been found to exhibit anti-HIV [5], antitrichinellosis [6], 
antinociceptive [7], antitumor activities [8], and other pharmacological activities [9–12]. For instance, 
it has been reported in recent literature that benzimidazolone bearing a sugar or piperidine residue on 
the aromatic nitrogen effectively inhibits the growth of bacteria [13,14].  
In previous studies, we synthesized a series of 1-acyl-3-isopropenyl-benzimidazol-2-ones, in which 
several derivatives of aromatic and α, β-unsaturated carboxylic acids showed strong activities against 
Botrytis cinerea, a plant pathogenic fungus that causes an important disease affecting vegetables and 
fruits [15]. In further investigation, their antibacterial activities against several strains of bacteria were 
assessed by broth micro-dilution method. The results showed that only 1-methacryloyl-3-isopropenyl-
benzimidazol-2-one exhibited extraordinary antibacterial activity, whereas other derivatives only showed 
minor or even no inhibition. A structure-activity relationship (SAR) study revealed that the presence of  
α, β-unsaturated carbonyl moiety is essential to the antibacterial activities of these derivatives. To better 
understand the SAR, a series of (28) 1-alkyl-3-methacryloyl (acryloyl)-benzimidazolone (thione) 
derivatives were synthesized and their antibacterial activities were evaluated herein. 
2. Results and Discussion 
2.1. Synthesis of 1-Alkyl-3-methacryloyl (Acryloyl)-benzimidazolone (Thione) 
For the synthesis of the title compounds, the reaction sequences outlined in Scheme 1 were 
followed, starting from 2(3H)-benzimidazolone (thione) (1), which was prepared by the reaction of  
O-phenylenediamine and urea or thiourea. Compound 1 was reacted with corresponding alkylhalide to 
obtain 1-alkyl-2(3H)-benzimidazolone (thione) (2), and the title compounds were then obtained by the 
reaction of 1-alkyl-2(3H)-benzimidazolone (thione) with corresponding acid chloride, which was 
prepared by the reaction of the carboxylic acids with thionyl chloride [16]. The chemical structures of 
the compounds have been elucidated by 
1H-NMR, 
13C-NMR and ESI-HRMS spectral analysis. 
Scheme 1. Synthetic route of the title compounds. 
 
2.2. Antibacterial Activities 
Antibacterial activities of the title compounds against standard bacterial strains were evaluated by the 
method of paper disc-diffusion, and the results are listed in Table 1. MICs of 1-alkyl-3-meth-acryloyl-Int. J. Mol. Sci. 2012, 13  4821 
 
 
benzimidazolone (thione) derivatives against tested bacterial strains were evaluated by the broth   
micro-dilution method, and the results are listed in Table 2. 
Table 1. Antibacterial activity of title compounds against five bacterial strains. 
Compounds 
Zone of inhibition (mm) 
B. cereus  B. subtilis E. coli  S. aureus  P. aeruginosa 
3aI (1-alkyl-3-methacryloyl-benzimidazolone) 
1 14(+++)  13(+++)  19(+++) 11(++)  15(+++) 
2 13(+++)  15(+++)  18(+++) 11(++)  14(+++) 
3 15(+++)  15(+++)  19(+++) -  20(+++) 
4 13(+++)  14(+++)  17(+++) -  16(+++) 
5 10(++)  12(++)  14(++)  10(+)  9(++) 
6 14(+++)  16(+++)  19(+++) 14(++)  16(+++) 
7 -  -  -  -  - 
3aII (1-alkyl-3-acryloyl-benzimidazolone) 
1 6(+)  7(+)  11(+)  - - 
2 7(+)  7(+)  -  - - 
3 7(+)  -  -  - - 
4 -  -  -  -  - 
5 10  8  -  -  - 
6 7  -  -  -  - 
7 -  -  -  -  - 
3bI (1-alkyl-3-methacryloyl-benzimidazolthione) 
1 13(+++)  13(+++)  15(+++) 13(++)  14(+++) 
2 12(+++)  13(+++)  19(+++) 11(++)  14(+++) 
3 14(+++)  14(+++)  18(+++) 9(+)  20(+++) 
4 12(+++)  13(+++)  17(+++) -  15(+++) 
5 9(++)  8(+)  10(++)  9(+)  9(++) 
6 12(+++)  11(+++)  15(+++) 12(+)  16(+++) 
7 -  -  -  -  - 
3bII (1-alkyl-3-acryloyl-benzimidazolthione) 
1 6(+)  6(+)  -  - - 
2 6(+)  -  12(+)  - - 
3 7(+)  -  -  - - 
4 -  -  -  -  - 
5 -  -  -  -  - 
6 7(+)  -  -  - - 
7 -  -  -  -  - 
Ampicillin 15(+++)  16(+++)  18(+++) 13(++) 20(+++) 
All values are means of three replicates; “-” means invisible “+” means eyeable, “++” means clear, “+++” 
means transparent. (Dose: 5 μg/disc). 
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Table 2. Minimum Inhibitory Concentrations (MICs) of 3aI and 3bI against five bacterial strains. 
Compounds 
MICs (μg/mL) 
B. cereus  B. subtilis  E. coli  S. aureus  P. aeruginosa 
3aI (1-alkyl-3-methacryloyl-benzimidazolone) 
1 6.25  3.13  3.13  25  25 
2 12.5  1.56  6.25  50  25 
3 3.13  3.13  1.56  >100  12.5 
4 12.5  6.25  12.5  >100  50 
5 100  100  >100  >100  >100 
6 6.25  12.5  1.56  12.5  50 
3bI (1-alkyl-3-methacryloyl-benzimidazolthione) 
1 12.5  6.25  12.5  50  25 
2 12.5  3.13  6.25  50  25 
3 3.13  6.25  3.13  >100  25 
4 25  12.5  6.25  >100  50 
5 >100  >100  >100  >100  >100 
6 12.5  25  3.13  25  100 
Ampicillin 6.25  1.56 3.13 6.25  25 
As shown in Table 1, except for benzyl (3aI7 and 3bI7), most other alkyl derivatives of 
methacryloyl benzimidazolone (thione) (3aI1~3aI6 and 3bI1~3bI6) showed extraordinary antibacterial 
activity against both gram-positive and gram-negative bacteria, whereas acryloyl derivatives exhibited 
weak or even no active against tested bacteria. This suggests that the presence of α, β-unsaturated 
carbonyl is essential to the antibacterial activities, and the methyl group substituted at α-position is also 
important. The loss of activity of benzyl derivatives (3aI7 and 3bI7) may be due to the steric hindrance 
of benzene ring. In Table 2, the activities of pentyl derivatives (3aI5 and 3bI5) decreased dramatically 
compared to those of other alkylated derivatives, which implies that a longer carbon chain is not 
favorable to the activity. Obviously, the introduction of different alkyl groups to the N1-position of the 
moiety of benzimidazolone had various affect on the activity, and 2–4 carbon substitutions may be 
more favorable for promoting the antibacterial activity as compared with much larger substitution 
groups at the same position. The antibacterial activities of 2-hydroxyl and 2-hydrosulfuryl 
benzimidazoles were almost identical, which indicates that these two groups had similar biological 
effects. These results have encouraged us to start further investigations into novel benzimidazolone 
(thione) derivatives as antibacterial agents and this will be reported in due course. 
3. Experimental Section  
3.1. General Experimental Procedures 
Melting points were measured on a WPR apparatus and are uncorrected (Shanghai Jingke Co., China). 
The 
1H-NMR (500 MHz), and 
13C-NMR (125 MHz) were obtained on a Bruker AM-500   
FT-NMR spectrometer with CDCl3 as the solvent and TMS as the internal standard. MS were recorded 
under ESI conditions using an APEX II FT-ICR mass spectrometer (Bruker Daltonics Inc.). Analytical Int. J. Mol. Sci. 2012, 13  4823 
 
 
thin layer chromatography (TLC) was carried out on precoated plates (silica gel), and spots were 
visualized with H2SO4/EtOH.  
3.2. Synthetic Procedures 
3.2.1. General Procedures for 1-Alkyl-Benzimidazolone (Thione) (2) 
To a solution of 1 (1 mmol) in methanol (10 mL) were added potassium carbonate (0.21 g, 1.5 mmol) 
and alkylhalide (1 mmol), and the mixture was refluxed for 4 h. The reaction was cooled and evaporated 
to dryness in vacuum. The residue was dissolved in 10 mL of water and 20 mL of ethyl acetate, and then 
stirred for 10 min. The organic layer was separated and washed with water followed by brine.   
The aqueous layer was extracted twice with ethyl acetate. The combined organic layers were dried over 
Na2SO4, concentrated under vacuum and the crude product was purified by flash chromatography on 
silica gel.  
3.2.2. General Procedures for 1-Alkyl-3-Methacryloyl (Acryloyl)-Benzimidazolone (Thione) (3) 
With nitrogen protection, to a solution of 2 (1 mmol) in anhydrous dichloromethane (10 mL) was 
added triethylamine (0.3 mL, 2.1 mmol). Carboxylic chloride (1 mmol) in dichloromethane (2 mL) 
was added in an ice-water bath, and the mixture was stirred for 5 h at room temperature. Saturated 
NaHCO3 solution (10 mL) was added, and the mixture was extracted by dichloromethane (3 × 15 mL). 
The organic extracts were combined, washed with water and saturated NaCl solution in that order, 
dried over Na2SO4, and finally concentrated under vacuum. After purification on a silica gel column, 
target compounds were obtained. 
1-ethyl-3-methacryloyl-1H-benzo[d]imidazol-2(3H)-one ( 3aI1):  white crystalline solid (0.145 g,   
63% yield), mp 60–62 °C. 
1H-NMR (500 MHz, CDCl3) δ 1.36 (t, J = 7.0 Hz, 3H), 2.15 (s, 3H),  
3.91 (q, J = 7.0 Hz, 2H), 5.54 (s, 1H), 5.55 (s, 1H), 7.01 (d, J = 8.0 Hz, 1H), 7.16 (t, J = 8.0 Hz, 1H), 
7.22–7.26 (m, 1H), 7.97 (d, J = 8.0 Hz, 1H); 
13C-NMR (125 MHz, CDCl3) δ 13.1, 19.0, 36.0, 107.7, 
115.0, 121.2, 122.4, 124.5, 126.6, 129.9, 140.7, 151.2, 170.4. ESI-MS: 231.1153 ([M+H]
+, 
[C13H14N2O2+H]
+; calc. 231.1134). 
1-propyl-3-methacryloyl-1H-benzo[d]imidazol-2(3H)-one (3aI2): white crystalline solid (0.136 g, 56% 
yield), mp 67–68 °C. 
1H-NMR (500 MHz, CDCl3) δ 0.99 (t, J = 7.0 Hz, 3H), 1.76–1.81 (m, 2H), 2.14 
(s, 3H), 3.81 (t, J  = 7.0 Hz, 2H), 5.53 (s, 1H), 5.55 (s, 1H), 7.00 (d, J  = 8.0 Hz, 1H),   
7.15 (t, J = 8.0 Hz, 1H),7.21–7.26 (m, 1H), 7.96 (d, J = 8.0 Hz, 1H); 
13C-NMR (125 MHz, CDCl3) δ 
11.3, 18.9, 21.3, 42.8, 107.8, 114.9, 121.2, 122.4, 124.4, 126.5, 130.4, 140.7, 151.6, 170.4. ESI-MS: 
245.1295 ([M+H]
+, [C14H16N2O2+H]
+; calc. 245.1290). 
1-isopropyl-3-methacryloyl-1H-benzo[d]imidazol-2(3H)-one  (3aI3): yellow oil (0.158 g, 65% yield). 
1H-NMR (500 MHz, CDCl3) δ 1.53 (d, J = 6.0 Hz, 6H), 2.14 (s, 3H), 4.62–4.64 (m, 1H), 5.52(s, 1H), 
5.54 (s, 1H), 7.11 (d, J = 8.0 Hz, 1H), 7.18–7.23 (m, 2H), 7.96 (d, J = 8.0 Hz, 1H); 
13C-NMR (125 MHz, 
CDCl3) δ 18.9, 21.7 (2CH3), 45.4, 108.9, 114.8, 121.0, 122.7, 124.3, 126.6, 129.3, 140.9, 150.9, 170.4. 
ESI-MS: 245.1280 ([M+H]
+, [C14H16N2O2+H]
+; calc. 245.1290). Int. J. Mol. Sci. 2012, 13  4824 
 
 
1-isobutyl-3-methacryloyl-1H-benzo[d]imidazol-2(3H)-one (3aI4): white solid (0.142 g, 55% yield), 
mp 55–56 °C. 
1H-NMR (500 MHz, CDCl3) δ 0.98 (d, J = 5.0 Hz, 6H), 2.14 (s, 3H), 2.19–2.22 (m, 1H), 
3.64 (d, J  = 6.5, 2H), 5.53 (s, 1H), 5.55 (s, 1H), 6.98 (d, J  = 8.0 Hz, 1H), 7.13–7.26 (m, 2H),   
7.96 (d, J = 8.0 Hz, 1H); 
13C-NMR (125 MHz, CDCl3) δ 18.9, 20.2 (2CH3), 27.6, 48.6, 108.1, 114.8, 
121.3, 122.4, 124.4, 126.5, 130.7, 140.7, 151.8, 170.4. ESI-MS: 259.1455 ([M+H]
+, [C15H18N2O2+H]
+; 
calc. 259.1447). 
1-pentyl-3-methacryloyl-1H-benzo[d]imidazol-2(3H)-one (3aI5): white solid (0.166 g, 61% yield), mp 
72–73 °C. 
1H-NMR (500 MHz, CDCl3)  δ 0.90 (CH3, br.s, 3H), 1.36 (2CH2, br.s, 4H),   
1.75–1.76 (m, 2H), 2.14 (s, 3H), 3.83 (t, J = 7.0 Hz, 2H), 5.54 (s, 1H), 5.55 (s, 1H), 6.98 (d, J = 8.0 Hz, 
1H), 7.06–7.23 (m, 2H), 7.96 (d, J = 8.0 Hz, 1H); 
13C-NMR (125 MHz, CDCl3) δ 13.9, 18.9, 22.3, 27.5, 
28.9, 41.2, 107.8, 114.9, 121.2, 122.4, 124.4, 126.6, 130.3, 140.7, 151.5, 170.4. ESI-MS: 273.1629 
([M+H]
+, [C16H20N2O2+H]
+; calc. 273.1603). 
1-allyl-3-methacryloyl-1H-benzo[d]imidazol-2(3H)-one (3aI6): white solid (0.140 g, 58% yield), mp 
42–44 °C. 
1H-NMR (500 MHz, CDCl3) δ 2.14 (s, 3H), 4.46 (d, J = 5.5 Hz, 2H), 5.26–5.29 (m, 2H), 
5.54 (s, 1H), 5.56 (s, 1H), 5.85–5.92 (m, 1H), 6.98 (d, J  = 8.0 Hz, 1H), 7.14–7.26 (m, 2H),   
7.96 (d, J = 8.0 Hz, 1H); 
13C-NMR (125 MHz, CDCl3) δ 18.9, 43.5, 108.4, 114.9, 118.4, 121.3, 122.6, 
124.5, 126.5, 130.1, 131.0, 140.6, 151.3, 170.3. ESI-MS: 243.1139 ([M+H]
+, [C14H14N2O2+H]
+; calc. 
243.1134). 
1-benzyl-3-methacryloyl-1H-benzo[d]imidazol-2(3H)-one (3aI7): white solid (0.188 g, 64% yield), mp 
112–114 °C. 
1H-NMR (500 MHz, CDCl3) δ 2.14 (s, 3H), 5.04 (s, 2H), 5.54 (s, 1H), 5.56 (s, 1H),  
6.89–6.92 (m, 1H), 7.14–7.16 (m, 2H), 7.24–7.34 (m, 5H), 8.22–8.25 (m, 1H); 
13C-NMR (125 MHz, 
CDCl3) δ 18.9, 44.8, 108.3, 116.2, 122.7, 124.6, 126.5, 127.5(2C), 128.1, 129.2(2C), 129.9, 132.0, 
135.2, 140.5, 151.7, 170.3. ESI-MS: 293.1289 ([M+H]
+, [C18H16N2O2+H]
+; calc. 293.1290). 
1-ethyl-3-acryloyl-1H-benzo[d]imidazol-2(3H)-one  (3aII1):  white crystalline solid  (0.117 g, 54% 
yield), mp 45–47 °C. 
1H-NMR (500 MHz, CDCl3) δ 1.36 (t, J = 7.0 Hz, 3H), 3.92 (q, J = 7.0 Hz, 2H), 
5.98 (d, J = 11.0 Hz, 1H), 6.67 (d, J = 17.0 Hz, 1H), 6.99 (d, J = 8.0 Hz, 1H), 7.14–7.26 (m, 2H),  
7.79 (dd, J = 17.0 Hz, 11.0 Hz, 1H), 8.24 (d, J = 8.0 Hz, 1H); 
13C-NMR (125 MHz, CDCl3) δ 13.1, 
36.0, 107.5, 116.1, 122.7, 124.7, 126.6, 129.2, 129.7, 131.8, 151.9, 165.3. ESI-MS: 217.0980 ([M+H]
+, 
[C12H12N2O2+H]
+; calc. 217.0977). 
1-propyl-3-acryloyl-1H-benzo[d]imidazol-2(3H)-one  (3aII2):  white solid  (0.115 g, 50% yield),  mp  
66–67 °C. 
1H-NMR (500 MHz, CDCl3)  δ  1.00 (t, J  = 7.0 Hz, 3H), 1.80 (q, J  = 7.0 Hz, 2H),   
3.83 (t, J = 7.0 Hz, 2H), 5.98 (d, J = 10.0 Hz, 1H), 6.67 (d, J = 17.0 Hz, 1H), 6.99 (d, J = 7.5 Hz, 1H), 
7.14–7.26 (m, 2H), 7.79 (dd, J = 17.0 Hz, 10.0 Hz, 1H), 8.24 (d, J = 7.5 Hz, 1H); 
13C NMR (125 MHz, 
CDCl3)  δ 11.3, 21.2, 42.8, 107.7, 116.1, 122.7, 124.7, 126.5, 129.3, 130.2, 131.8, 152.3, 165.4.   
ESI-MS: 231.1139 ([M+H]
+, [C13H14N2O2+H]
+; calc. 231.1134). 
1-isopropyl-3-acryloyl-1H-benzo[d]imidazol-2(3H)-one (3aII3): white solid (0.138 g, 60% yield), mp 
93–95 °C. 
1H-NMR (500 MHz, CDCl3)  δ  1.56 (d, J  = 5.0 Hz, 6H), 4.68–4.70 (m, 1H),   
5.97 (d, J = 10.0 Hz, 1H), 6.65 (d, J = 16.5 Hz, 1H), 7.13–7.26 (m, 2H), 7.76 (dd, J = 16.5 Hz,  
10.0 Hz, 1H), 8.25 (d, J = 7.5 Hz, 1H); 
13C-NMR (125 MHz, CDCl3) δ 19.8, 45.4, 108.8, 116.1, 122.3, Int. J. Mol. Sci. 2012, 13  4825 
 
 
124.4, 126.7, 129.1, 129.5, 131.6, 151.6, 165.5. ESI-MS: 231.1130 ([M+H]
+, [C13H14N2O2+H]
+; calc. 
231.1134). 
1-isobutyl-3-acryloyl-1H-benzo[d]imidazol-2(3H)-one (3aII4): white solid (0.151 g, 62% yield), mp 
106–108 °C. 
1H-NMR (500 MHz, CDCl3)  δ  1.00 (d, J  = 5.0 Hz, 6H), 2.21–2.23 (m, 1H),   
3.66 (d, J = 6.0 Hz, 2H), 5.98 (d, J = 10.5 Hz, 1H), 6.67 (d, J = 17.0 Hz, 1H), 6.97 (d, J = 7.5 Hz, 1H), 
7.14–7.26 (m, 2H), 7.79 (dd, J = 16.0 Hz, 11.0 Hz, 1H), 8.23 (d, J = 7.5 Hz, 1H); 
13C-NMR (125 MHz, 
CDCl3) δ 20.2(2CH3), 27.6, 48.6, 107.9, 116.0, 122.6, 124.6, 126.5, 129.3, 130.5, 131.8, 152.5, 165.4. 
ESI-MS: 245.1291 ([M+H]
+, [C14H16N2O2+H]
+; calc. 245.1290). 
1-pentyl-3-acryloyl-1H-benzo[d]imidazol-2(3H)-one  (3aII5):  white solid  (0.163 g, 63% yield),  mp  
54–56 °C. 
1H-NMR (500 MHz, CDCl3) δ 0.89 (t, J = 6.0 Hz, 3H), 1.34–1.36(m, 4H), 1.70–1.73 (m, 2H), 
3.78 (t, J  = 7.5 Hz, 2H), 5.93 (dd, J  = 10.5, 1.5 Hz, 1H), 6.63 (dd, J  = 1.5, 17.0 Hz, 1H),   
6.91 (d, J = 8.0 Hz, 1H), 7.04–7.17 (m, 2H), 7.78 (dd, J = 10.5 Hz, 17.0 Hz, 1H), 8.15 (d, J = 8.0 Hz, 
1H); 
13C-NMR (125 MHz, CDCl3) δ 13.9, 22.3, 27.5, 28.9, 41.0, 107.5, 115.8, 122.4, 124.5, 126.4, 
129.3, 130.0, 131.4, 152.0, 165.0. ESI-MS: 259.1450 ([M+H]
+, [C15H18N2O2+H]
+; calc. 259.1447). 
1-allyl-3-acryloyl-1H-benzo[d]imidazol-2(3H)-one  (3aII6):  yellow oil  (0.135 g, 59% yield).   
1H-NMR (500 MHz, CDCl3) δ 4.49–4.50 (d, J = 4.0 Hz, 2H), 5.25–5.29 (m, 2H), 5.87–5.92 (m, 1H), 
5.99 (d, J = 10.0 Hz, 1H), 6.68 (d, J = 17.0 Hz, 1H), 6.97 (d, J = 8.0 Hz, 1H), 7.14–7.26 (m, 2H),  
7.79 (dd, J = 17.0 Hz, 10.0 Hz, 1H), 8.24 (d, J = 8.0 Hz, 1H); 
13C-NMR (125 MHz, CDCl3) δ 43.4, 
108.2, 116.0, 118.3, 122.9, 124.7, 126.5, 129.2, 129.9, 130.9, 132.0, 152.0, 165.3. ESI-MS: 229.0980 
([M+H]
+, [C13H12N2O2+H]
+; calc. 229.0977). 
1-benzyl-3-acryloyl-1H-benzo[d]imidazol-2(3H)-one ( 3aII7): white solid (0.206 g, 74% yield),  mp 
118–119 °C. 
1H-NMR (500 MHz, CDCl3)  δ 5.05 (s, 2H), 6.01 (dd, J  = 10.0, 1.5 Hz, 1H),   
6.69 (dd, J  = 17.5, 1.5 Hz, 1H), 6.89–6.91 (m, 1H), 7.13–7.16 (m,2H), 7.26–7.34 (m, 5H),   
7.83 (dd, J = 10.0, 1.5 Hz, 1H), 8.23–8.25 (m, 1H). 
13C-NMR (125 MHz, CDCl3) δ 44.9, 108.3, 116.1, 
122.9, 124.8, 126.5, 127.5(2C), 128.1, 129.0(2C), 129.2, 129.9, 132.0, 135.2, 152.5, 165.3. ESI-MS: 
279.1133 ([M+H]
+, [C17H14N2O2+H]
+; calc. 279.1134). 
1-ethyl-3-methacryloyl-1H-benzo[d]imidazol-2(3H)-thione (3bI1): white solid (0.128 g, 52% yield), 
mp 38–39 °C. 
1H-NMR (500 MHz, CDCl3) δ 1.44 (t, J = 7.5 Hz, 3H), 2.19 (s, 3H), 3.33 (q, J = 7.5 Hz, 
2H), 5.70 (s, 1H), 5.82 (s, 1H), 7.20–7.29 (m, 2H), 7.59 (d, J = 8.0 Hz, 1H), 7.63 (d, J = 8.0 Hz, 1H);  
13C-NMR (125 MHz, CDCl3) δ 14.0, 18.6, 27.4, 113.4, 118.5, 123.2, 124.3, 126.1, 134.1, 139.3, 143.9, 
154.4, 169.1. ESI-MS: 247.0900 ([M+H]
+, [C13H14N2OS+H]
+; calc. 247.0905). 
1-propyl-3-methacryloyl-1H-benzo[d]imidazol-2(3H)-thione (3bI2): yellow oil (0.158 g, 61% yield). 
1H-
NMR (500 MHz, CDCl3)  δ  1.07 (t, J  = 7.0 Hz, 3H), 1.81 (q, J  = 7.0 Hz, 2H), 2.18 (s, 3H),   
3.30 (t, J = 7.0 Hz, 2H), 5.68 (s, 1H), 5.80 (s, 1H), 7.18 (t, J = 7.5, 1H), 7.25 (t, J = 7.5, 1H),  
7.57 (d, J = 7.5 Hz, 1H), 7.61 (d, J = 7.5 Hz, 1H); 
13C-NMR (125 MHz, CDCl3) δ 13.5, 18.5, 22.2, 
35.0, 113.4, 118.5, 123.2, 124.2, 126.1, 134.1, 139.3, 143.9, 154.5, 169.0. ESI-MS: 261.1063 ([M+H]
+, 
[C14H16N2OS+H]
+; calc. 261.1062). 
1-isopropyl-3-methacryloyl-1H-benzo[d]imidazol-2(3H)-thione (3bI3): yellow oil (0.148 g, 57% yield). 
1H-NMR (500 MHz, CDCl3)  δ  1.46 (d, J  = 6.5 Hz, 6H), 2.17 (s, 3H), 4.13–4.15 (m, 1H),   Int. J. Mol. Sci. 2012, 13  4826 
 
 
5.66 (s, 1H), 5.79 (s, 1H), 7.18–7.27 (m, 2H), 7.57 (d, J = 8.0 Hz, 1H), 7.62 (d, J = 8.0 Hz, 1H);  
13C-NMR (125 MHz, CDCl3) δ 18.5, 23.0(2CH3), 39.1, 113.3, 118.5, 123.3, 124.2, 126.3, 133.9, 139.4, 
143.9, 153.8, 169.1. ESI-MS: 261.1063 ([M+H]
+, [C14H16N2OS+H]
+; calc. 261.1062). 
1-isobutyl-3-methacryloyl-1H-benzo[d]imidazol-2(3H)-thione (3bI4): white solid (0.176 g, 64% yield), 
mp 55–57 °C. 
1H-NMR (500 MHz, CDCl3)  δ  1.07 (d, J  = 5.0 Hz, 6H), 2.04–2.06 (m, 1H),   
2.19 (s, 3H), 3.24 (d, J = 5.0 Hz, 2H), 5.69 (s, 1H), 5.82 (s, 1H), 7.18–7.28 (m, 2H), 7.57 (d, J = 8.0 Hz, 
1H), 7.62 (d, J = 8.0 Hz, 1H); 
13C-NMR (125 MHz, CDCl3) δ 18.5, 22.1, 28.1, 41.6, 113.3, 118.5, 
123.2, 124.2, 126.2, 134.2, 139.3, 143.8, 154.8, 169.1. ESI-MS: 275.1213 ([M+H]
+, [C15H18N2OS+H]
+; 
calc. 275.1218). 
1-pentyl-3-methacryloyl-1H-benzo[d]imidazol-2(3H)-thione (3bI5): yellow oil (0.196 g, 68% yield). 
1H-NMR (500 MHz, CDCl3) δ 0.91 (d, J = 7.5 Hz, 3H), 1.33–1.47 (m, 4H), 1.74–1.78 (m, 2H),  
2.16 (s, 3H), 3.31 (t, J = 7.5 Hz, 2H), 5.66 (s, 1H), 5.77 (s, 1H), 7.14–7.25 (m, 2H), 7.55 (d, J = 8.0 Hz, 
1H), 7.60 (d, J = 8.0 Hz, 1H); 
13C-NMR (125 MHz, CDCl3) δ 13.9, 18.5, 22.2, 28.4, 31.0, 33.0, 113.4, 
118.5, 123.1, 124.2, 126.0, 134.1, 139.2, 143.9, 154.5, 168.9. ESI-MS: 289.1373 ([M+H]
+, 
[C16H20N2OS+H]
+; calc. 289.1375). 
1-allyl-3-methacryloyl-1H-benzo[d]imidazol-2(3H)-thione  (3bI6): colorless oil  (0.137g, 53% yield). 
1H-NMR (500 MHz, CDCl3)  δ  2.16 (s, 3H), 3.97 (d, J  = 7.5 Hz, 2H), 5.16 (d, J  = 10.5, 1H),   
5.35 (dd, J = 17.0, 1.0 Hz, 1H), 5.67 (s, 1H), 5.78 (s, 1H), 5.98–6.06 (m, 1H), 7.16–7.26 (m, 2H),  
7.57 (d, J = 8.0 Hz, 1H), 7.60 (d, J = 8.0 Hz, 1H); 
13C-NMR (125 MHz, CDCl3) δ 13.9, 18.5, 22.2, 
28.4, 31.0, 33.0, 113.4, 118.5, 123.1, 124.2, 126.0, 134.1, 139.2, 143.9, 154.5, 168.9. ESI-MS: 
259.0503 ([M+H]
+, [C14H14N2OS+H]
+; calc. 259.0509). 
1-benzyl-3-methacryloyl-1H-benzo[d]imidazol-2(3H)-thione ( 3bI7): colorless oil  (0.215g, 69% yield). 
1H-NMR (500 MHz, CDCl3) δ 2.16 (s, 3H), 4.57 (s, 2H), 5.68 (s, 1H), 5.79 (s, 1H), 7.20–7.34 (m, 5H), 
7.43–7.45 (m, 2H), 7.60 (d, J = 8.0, 1H), 7.66 (d, J = 8.0, 1H). 
13C-NMR (125 MHz, CDCl3) δ 18.6, 
37.8, 113.5, 118.6, 123.4, 124.4, 126.1, 127.7, 128.7(2C), 129.4(2C), 134.1, 136.2, 139.2, 143.8, 154.1, 
168.9. ESI-MS: 309.1065 ([M+H]
+, [C18H16N2OS+H]
+; calc. 309.1062). 
1-ethyl-3-acryloyl-1H-benzo[d]imidazol-2(3H)-thione (3bII1): white solid (0.132 g, 57% yield), mp 
82–83 °C. 
1H-NMR (500 MHz, CDCl3)  δ  1.48 (t, J  = 7.5 Hz, 3H), 3.36 (q, J  = 7.5 Hz, 2H),   
6.16 (d, J = 10.5 Hz, 1H), 6.73 (d, J = 17.0 Hz, 1H), 7.04–7.10 (dd, J = 17.0, 10.5 Hz, 1H), 7.23–7.33 (m, 2H), 
7.63–7.66 (m, 2H),; 
13C-NMR (125 MHz, CDCl3) δ 13.9, 27.0, 113.4, 118.8, 123.3, 124.6, 129.4, 
133.2, 133.8, 144.2, 154.7, 164.4. ESI-MS: 233.0743 ([M+H]
+, [C12H12N2OS+H]
+; calc. 233.0749). 
1-propyl-3-acryloyl-1H-benzo[d]imidazol-2(3H)-thione (3bII2): white solid (0.160 g, 65% yield), mp 
100–102 °C. 
1H-NMR (500 MHz, CDCl3)  δ  1.08 (t, J  = 7.5 Hz, 3H), 1.83–1.85 (m, 2H),   
3.42 (q, J = 7.5 Hz, 2H), 6.16 (d, J = 10.5 Hz, 1H), 6.73 (d, J = 17.0 Hz, 1H), 7.07 (dd, J = 17.0, 10.5 Hz, 1H), 
7.23–7.33 (m, 2H), 7.63–7.66 (m, 2H),; 
13C-NMR (125 MHz, CDCl3) δ 13.4, 22.7, 38.8, 113.5, 118.7, 
123.3, 124.6, 129.5, 133.3, 133.7, 144.1, 154.9, 164.4. ESI-MS: 247.0910 ([M+H]
+, [C13H14N2OS+H]
+; 
calc. 247.0905). 
1-isopropyl-3-acryloyl-1H-benzo[d]imidazol-2(3H)-thione (3bII3): white solid (0.130 g, 53% yield), mp 
102–103 °C. 
1H-NMR (500 MHz, CDCl3)  δ  1.51 (d, J  = 6.0 Hz, 6H), 4.18–4.20 (m, 1H),   Int. J. Mol. Sci. 2012, 13  4827 
 
 
6.15 (d, J = 10.5, 1H), 6.72 (d, J = 17.0, 1H), 7.07 (dd, J = 17.0, 10.5 Hz, 1H), 7.23–7.26 (m, 1H),  
7.29–7.32 (m, 1H), 7.64–7.66 (m, 2H); 
13C-NMR (125 MHz, CDCl3) δ 23.0 (2CH3), 37.8, 113.5, 118.7, 
123.3, 124.5, 129.6, 133.1, 133.6, 144.3, 154.1, 164.4. ESI-MS: 247.0910 ([M+H]
+, [C13H14N2OS+H]
+; 
calc. 247.0905). 
1-isobutyl-3-acryloyl-1H-benzo[d]imidazol-2(3H)-thione (3bII4): colorless oil (0.153 g, 59% yield). 
1H-
NMR (500 MHz, CDCl3) δ 1.10 (d, J = 6.0 Hz, 6H), 2.08–2.10 (m, 1H), 3.28 (d, J = 6.0 Hz, 2H), 6.13 
(d, J = 10.5, 1H), 6.69 (d, J = 17.0, 1H), 7.06 (dd, J = 17.0, 10.5 Hz, 1H), 7.21–7.28 (m, 2H),  
7.59–7.62 (m, 2H); 
13C-NMR (125 MHz, CDCl3) δ 22.2 (2CH3), 28.0, 41.1, 113.5, 118.7, 123.3, 124.5, 
129.5, 133.3, 133.7, 144.1, 155.0, 164.4. ESI-MS: 261.1050 ([M+H]
+, [C14H16N2OS+H]
+;  
calc. 261.1062). 
1-pentyl-3-acryloyl-1H-benzo[d]imidazol-2(3H)-thione (3bII5): colorless oil (0.186 g, 64% yield). 
1H-
NMR (500 MHz, CDCl3)  δ  0.88 (t, J  = 6.0 Hz, 3H), 1.35–1.38 (m, 4H), 1.77–1.80 (m, 2H),   
3.53 (t, J = 7.5 Hz, 2H), 6.14 (d, J = 10.5), 6.70 (d, J = 17.0 Hz, 1H), 7.04 (dd, J = 17.0,10.5 Hz, 1H), 
7.22–7.29 (m, 2H), 7.60–7.62 (m, 2H); 
13C-NMR (125 MHz, CDCl3) δ 14.0, 22.2, 28.0, 29.0, 38.7, 
113.6, 118.8, 123.3, 124.6, 129.4, 133.2, 133.7, 144.1, 152.0, 164.4. ESI-MS: 275.1211 ([M+H]
+, 
[C15H18N2OS+H]
+; calc. 275.1218). 
1-allyl-3-acryloyl-1H-benzo[d]imidazol-2(3H)-thione  (3bII6): white solid (0.161 g, 66% yield), mp 
104–106 °C. 
1H-NMR (500 MHz, CDCl3) δ 4.02 (d, J = 7.0 Hz, 2H), 5.15 (d, J = 10.0 Hz, 1H),  
5.36 (dd, J = 16.5 Hz, 1H), 6.04–6.07 (m, 1H), 6.16 (d, J = 10.5, 1H), 6.72 (d, J = 17.0 Hz, 1H),  
7.05 (dd, J = 17.0, 10.5 Hz, 1H), 7.22–7.29 (m, 2H), 7.60–7.62 (m, 2H); 
13C-NMR (125 MHz, CDCl3)  
δ  35.5, 113.4, 119.1, 123.4, 124.6, 129.3, 132.6, 133.9, 143.5, 154.2, 164.3. ESI-MS: 245.0741 
([M+H]
+, [C13H12N2OS+H]
+; calc. 245.0749). 
1-benzyl-3-acryloyl-1H-benzo[d]imidazol-2(3H)-thione (3bII7): colorless oil (0.223 g, 76% yield). 
1H-
NMR (500 MHz, CDCl3) δ 4.56 (s, 2H), 6.00 (dd, J = 10.0, 1.5 Hz, 1H), 6.68 (dd, J = 17.5, 1.5 Hz, 
1H), 6.89–6.91 (m, 1H), 7.13–7.15 (m,2H), 7.27–7.34 (m, 5H), 7.83 (dd, J  = 10.0, 1.5 Hz, 1H),   
8.24–8.26(m, 1H). 
13C-NMR (125 MHz, CDCl3) δ 37.9, 113.6, 119.1, 123.5, 124.7, 127.5(2C), 128.1, 
129.1(2C), 129.3, 133.0, 133.9, 135.4, 143.8, 154.1, 164.5. ESI-MS: 295.0902 ([M+H]
+, 
[C17H14N2OS+H]
+; calc. 295.0905). 
3.3. Antibacterial Activity  
Antibacterial activities 3a(b)I1-7~3a(b)II1-7 were carried out by paper disc-diffusion method [17]. 
The standard bacterial strains Bacillus cereus (1.1846), Bacillus subtilis (1.88), Staphylococcus aureus 
(1.89),  Escherichia coli (1.1574), and Pseudomonas aeruginosa (1.2031) were obtained from the 
China General Microbiological Culture Collection Center. Ampicillin sodium (Sigma, Shanghai, China) 
was used as positive control. Standardized inoculum (5 × 10
5 cfu/mL) of each test bacterium was 
spread on to sterile Müller-Hinton agar (Hangzhou Microbial Reagent Co. Ltd., Zhejiang, China) 
plates so as to achieve a confluent growth. The title compounds were dissolved in dichloromethane at 
the concentration of 1 mg/mL, and then 5 μL of the solutions were transfered onto discs (diameter,  
6 mm) punched from Whatman no. 1 filiter paper, so that the disc contained 5 μg of the compound. 
After the solvent was evaporated, the sample discs were placed gently on the previously-marked zones Int. J. Mol. Sci. 2012, 13  4828 
 
 
in the agar plates. Standard ampicillin (5 μg/disc) paper disc (diameter, 6 mm) was used as positive 
controls. The plates were allowed to stand for 1 h at 4 °C for diffusion to take place and then incubated 
at 37 °C for 24 h. The diameter of inhibition zone around each disc was measured and recorded at the 
end of the incubation period. Experiments were repeated triplicate and the average values are   
reported here. 
3.4. Minimum Inhibitory Concentrations (MICs)  
MICs of compounds 3a(b)I1-6 against five strains of bacteria were evaluated by the broth mciro- dilution 
method in 96-well plates [18]. The inoculum was prepared by suspending several colonies from an 
overnight culture of test bacteria from 0.5% sheep blood agar media in Müller-Hinton broth, and a 
adjusting to a 0.5 McFarland standard (approximately 1.5 × 10
8 colony-forming units per mL).   
A further dilution of 1:200 was made by placing 0.25 mL of the adjusted suspension into 49.75 mL of 
Müller-Hinton broth. The compounds were firstly dissolved in DMSO at the concentration of 10 mg/mL, 
and it was diluted ten-fold with sterile water to give the stock solution. Two-fold serial dilutions of the 
tested compounds were prepared in Müller-Hinton broth. Then the dilutions and inoculated suspension 
of the bacteria were delivered to wells of a 96-well plate at the ratio of 1:1. The final concentration of 
inoculum in each well was 3.7 × 10
5 colony-forming units per mL. After incubation for 24 h at 30 °C, 
the MICs were read. Experiments were repeated in triplicate and standard ampicillin was used as the 
positive control.  
4. Conclusions  
In summary, 28 new 1-alkyl-3-methacryloyl (acryloyl) derivatives of benzimidazolone (thione) 
(3a(b)I1-7~3a(b)II1-7) were synthesized and evaluated for their antibacterial activities against five 
standard bacterial strains in vitro. The bioassay of these analogues showed that all synthesized   
N3-methacryloyl-derivatives of benzimidazolone (thione) exhibited stronger active against tested 
bacterial strains, whereas the acryloyl-derivatives were weaker or inactive against tested bacterial 
strains. The data suggest that the substitutions of N3 have a notable influence on the antibacterial 
activity of the title compounds. In addition, 2–4 carbon substitutions may be more favorable for 
promoting the antibacterial activity as compared with much larger substitution groups at the N1 
position. These results have encouraged us to start further investigations into novel benzimidazolone 
(thione) derivatives as antibacterial agents and this will be reported in due course. 
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